• What We Do

    Building a pipeline of unique assets enabled by a world-leading platform for antibody discovery

    HEPTAD

    An unparalleled platform for the targeting GPCRs with antibodies

    HEPTAD is DJS Antibodies' proprietary antibody discovery technology and delivers unprecedented success rates in the discovery of functional antibodies to GPCRs. It is built on a deep understanding of immunology and antibody production enabling us to discover functional antibodies to complex protein targets which have hitherto been intractable to drug discovery.

    Asset Development

    Creating value through the development of unique therapeutics

    We use HEPTAD to discover antibodies against challenging GPCR targets where there is a strong commercial case for an antibody therapeutic. Lead antibodies discovered with HEPTAD are fed into our antibody development pipeline where our expert team works to accelerate their development through preclinical milestones and into the clinic.

  • Pipeline

    We are building a unique pipeline of unique first-in-class antibody assets

    Oncology

    DJS-001

    DJS-001 targets the tumour microenvironment to alleviate immunosuppression and enhance checkpoint inhibitor efficacy.

     

    DJS has produced a panel of lead antibodies which out-perform existing antagonist molecules.

    Chronic Kidney Disease

    DJS-002

    DJS-002 targets the key processes of fibrosis and filtration unit breakdown associated with CKD.

     

    DJS has produced the first ever functional antibodies shown to antagonise signalling through this GPCR.

    Rare Genetic Disease

    DJS-003

    DJS-003 hits a clinically validated target in a patient population where there is a high need for prophylactic treatments.

     

    DJS has produced the first ever antibodies which bind to this receptor in its native conformation.

  • Our Team

    Board of Directors

    David Llewellyn

    CEO

    David completed a DPhil in Clinical Medicine at the University of Oxford as a Rhodes Scholar. He is an expert in the generation and characterisation of antibodies and has developed novel techniques for immune modulation.

    Joe Illingworth

    CSO

    Joe has a background in biochemistry and immunology. He completed a DPhil and Post-doctoral work at the University of Oxford on antibody inducing vaccines. His expertise include inducing potent antibody responses to proteins which are difficult to express recombinantly.

    Graeme Martin

    Chairperson

    Graeme has a background in pharmaceutical R&D with Glaxo Wellcome and Roche having seen multiple programmes through preclinical development and into the clinic. Most recently, he has led Takeda Ventures as CEO, and has been working with DJS for 3 years.

    Andrew McLean

    Director

    Andy is a Principal at Oxford Sciences Innovation (OSI); an investment company formed to turn Oxford’s world beating science in world changing companies. Prior to joining OSI Andy trained as a physician and consulted in the pharmaceutical & biotech practice at McKinsey.

  • Join our team

    If you're looking to be surrounded by fantastic people and join an exciting team working on the cutting edge of drug discovery, get in touch!